Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.
Chase Heibel
Advertisement
Chase Heibel is director and general manager, controlled temperature technologies, at Thermo Fisher Scientific.
Articles by Chase Heibel
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How CMS’ Final Negotiation Rule Treats New Drug Formulations
2
Report: 2026 Patient Support Awards Name Leaders in Large, Small Pharma
3
Big Three Distributors Lean on Specialty for Profit Growth
4
ELPRO CEO on How Biologics Raised the Stakes in Cold Chain Handling
5